# Brian D Robinson

## List of Publications by Citations

**Source:** https://exaly.com/author-pdf/179223/brian-d-robinson-publications-by-citations.pdf
**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 95 papers | 6,355 citations | 26 h-index | 79 g-index |
| 101 ext. papers | 8,238 ext. citations | 7.4 avg, IF | 4.7 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 95 | Integrative clinical genomics of advanced prostate cancer. *Cell*, **2015**, 161, 1215-1228 | 56.2 | 1765 |
| 94 | The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **2015**, 163, 1011-25 | 56.2 | 1713 |
| 93 | Genomic correlates of clinical outcome in advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11428-11436 | 11.5 | 383 |
| 92 | Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. *Clinical Cancer Research*, **2009**, 15, 2433-41 | 12.9 | 264 |
| 91 | N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. *Cancer Cell*, **2016**, 30, 563-577 | 24.3 | 256 |
| 90 | Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. *JAMA Oncology*, **2015**, 1, 466-74 | 13.4 | 207 |
| 89 | Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. *Cancer Research*, **2013**, 73, 2718-36 | 10.1 | 174 |
| 88 | Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. *Journal of the National Cancer Institute*, **2014**, 106, | 9.7 | 125 |
| 87 | SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. *Cancer Cell*, **2017**, 31, 436-451 | 24.3 | 116 |
| 86 | SPOP mutations in prostate cancer across demographically diverse patient cohorts. *Neoplasia*, **2014** , 16, 14-20 | 6.4 | 113 |
| 85 | Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. *Nature Communications*, **2019**, 10, 2977 | 17.4 | 71 |
| 84 | RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. *Cancer Discovery*, **2014**, 4, 318-33 | 24.4 | 65 |
| 83 | A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. *Journal of Urology*, **2014**, 191, 1439-45 | 2.5 | 62 |
| 82 | N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. *Journal of Clinical Investigation*, **2019**, 129, 3924-3940 | 15.9 | 55 |
| 81 | MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. *Cancer Discovery*, **2015**, 5, 636-51 | 24.4 | 52 |
| 80 | Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. *Npj Genomic Medicine*, **2016**, 1, | 6.2 | 51 |
| 79 | Possible germ cell-Sertoli cell interactions are critical for establishing appropriate expression levels for the Sertoli cell-specific MicroRNA, miR-202-5p, in human testis. *Basic and Clinical Andrology*, **2015**, 25, 2 | 2.8 | 45 |

| | | | |
|---|---|---|---|
| 78 | Intraductal carcinoma of the prostate. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 418-25 | 5 | 41 |
| 77 | The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 461-493 | 5 | 41 |
| 76 | miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. *Experimental Cell Research*, **2016**, 348, 190-200 | 4.2 | 40 |
| 75 | Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow. *Cancer Research*, **2016**, 76, 2453-64 | 10.1 | 38 |
| 74 | The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. *European Urology Oncology*, **2019**, 2, 135-140 | 6.7 | 30 |
| 73 | CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. *Cancer Cell*, **2019**, 35, 603-617.e8 | 24.3 | 29 |
| 72 | Outcomes of microdissection testicular sperm extraction in men with nonobstructive azoospermia due to maturation arrest. *Fertility and Sterility*, **2015**, 104, 569-73.e1 | 4.8 | 28 |
| 71 | Targeted suppression of AR-V7 using PIP5K1 inhibitor overcomes enzalutamide resistance in prostate cancer cells. *Oncotarget*, **2016**, 7, 63065-63081 | 3.3 | 28 |
| 70 | The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. *Journal of Cell Biology*, **2017**, 216, 641-656 | 7.3 | 27 |
| 69 | Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. *Cancer*, **2018**, 124, 1008-1015 | 6.4 | 24 |
| 68 | Analyses of the transcriptome and metabolome demonstrate that HIF1 mediates altered tumor metabolism in clear cell renal cell carcinoma. *PLoS ONE*, **2015**, 10, e0120649 | 3.7 | 23 |
| 67 | SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. *Journal of Clinical Investigation*, **2018**, 128, 381-386 | 15.9 | 23 |
| 66 | Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. *European Urology Oncology*, **2020**, 3, 10-20 | 6.7 | 23 |
| 65 | Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. *Human Pathology*, **2014**, 45, 2136-43 | 3.7 | 22 |
| 64 | Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. *European Urology*, **2014**, 66, 379-85 | 10.2 | 21 |
| 63 | Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. *Advances in Urology*, **2014**, 2014, 627290 | 1.6 | 21 |
| 62 | Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. *Journal of Pathology*, **2019**, 249, 79-89 | 9.4 | 20 |
| 61 | A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. *ELife*, **2020**, 9, | 8.9 | 19 |

| | | | |
|---|---|---|---|
| 60 | Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. *Cancer Research*, **2018**, 78, 348-358 | 10.1 | 19 |
| 59 | Ubiquitin Specific Protease 26 (USP26) expression analysis in human testicular and extragonadal tissues indicates diverse action of USP26 in cell differentiation and tumorigenesis. *PLoS ONE*, **2014**, 9, e98638 | 3.7 | 18 |
| 58 | Rapid evaluation of fresh ex vivo kidney tissue with full-field optical coherence tomography. *Journal of Pathology Informatics*, **2015**, 6, 53 | 4.4 | 18 |
| 57 | Improved correlation of urinary cytology specimens using The Paris System in biopsy-proven upper tract urothelial carcinomas. *Cancer Cytopathology*, **2018**, 126, 498-504 | 3.9 | 16 |
| 56 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. *JCO Precision Oncology*, **2019**, 3, | 3.6 | 15 |
| 55 | Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *Journal of Urology*, **2014**, 191, 830-41 | 2.5 | 15 |
| 54 | An emerging role for cytopathology in precision oncology. *Cancer Cytopathology*, **2016**, 124, 167-73 | 3.9 | 14 |
| 53 | Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome. *Methods*, **2015**, 77-78, 197-204 | 4.6 | 12 |
| 52 | Multiphoton gradient index endoscopy for evaluation of diseased human prostatic tissue ex vivo. *Journal of Biomedical Optics*, **2014**, 19, 116011 | 3.5 | 12 |
| 51 | The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. *European Urology Oncology*, **2018**, 1, 263-267 | 6.7 | 11 |
| 50 | Diagnosis and Genotyping of Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement Using Next-Generation Sequencing of Plasma Microbial Cell-Free DNA. *Open Forum Infectious Diseases*, **2019**, 6, ofz242 | 1 | 11 |
| 49 | Real-time in vivo periprostatic nerve tracking using multiphoton microscopy in a rat survival surgery model: a promising pre-clinical study for enhanced nerve-sparing surgery. *BJU International*, **2015**, 116, 478-86 | 5.6 | 11 |
| 48 | Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. *BJU International*, **2016**, 118, 243-9 | 5.6 | 11 |
| 47 | Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 495.e15-22 | 2.8 | 10 |
| 46 | Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients. *Clinical Cancer Research*, **2020**, 26, 1915-1923 | 12.9 | 9 |
| 45 | The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology. *Oncology Letters*, **2018**, 16, 1641-1649 | 2.6 | 9 |
| 44 | Microsurgical rat varicocele model. *Journal of Urology*, **2014**, 191, 548-53 | 2.5 | 9 |
| 43 | Multiphoton microscopy for rapid histopathological evaluation of kidney tumours. *BJU International*, **2016**, 118, 118-26 | 5.6 | 9 |

| | | | |
|---|---|---|---|
| 42 | Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. *JCO Precision Oncology*, **2019**, 3, | 3.6 | 8 |
| 41 | Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. *Placenta*, **2017**, 56, 79-85 | 3.4 | 7 |
| 40 | Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease. *Cancer Genetics*, **2016**, 209, 11-20 | 2.3 | 7 |
| 39 | Identification of spermatogenesis in a rat sertoli-cell only model using Raman spectroscopy: a feasibility study. *Journal of Urology*, **2014**, 192, 607-12 | 2.5 | 7 |
| 38 | Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. *Bladder Cancer*, **2017**, 3, 161-169 | 1 | 7 |
| 37 | Pathologic Outcomes following Urethral Diverticulectomy in Women. *Advances in Urology*, **2014**, 2014, 861940 | 1.6 | 6 |
| 36 | Common germline-somatic variant interactions in advanced urothelial cancer. *Nature Communications*, **2020**, 11, 6195 | 17.4 | 6 |
| 35 | Comparative pathology of dog and human prostate cancer. *Veterinary Medicine and Science*, **2021**, | 2.1 | 5 |
| 34 | Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study. *Journal of Urology*, **2020**, 203, 530-536 | 2.5 | 5 |
| 33 | Magnetic resonance microscopy may enable distinction between normal histomorphological features and prostate cancer in the resected prostate gland. *BJU International*, **2017**, 119, 414-423 | 5.6 | 4 |
| 32 | Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. *Cell Reports*, **2021**, 36, 109625 | 10.6 | 4 |
| 31 | Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *Journal of Urology*, **2017**, 198, 1269-1277 | 2.5 | 3 |
| 30 | G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. *Nature Communications*, **2021**, 12, 6662 | 17.4 | 3 |
| 29 | The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. *Journal of Urology*, **2019**, 202, 96-101 | 2.5 | 3 |
| 28 | Copolymerization of single-cell nucleic acids into balls of acrylamide gel. *Genome Research*, **2020**, 30, 49-61 | 9.7 | 3 |
| 27 | Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. *Nature Communications*, **2021**, 12, 3372 | 17.4 | 3 |
| 26 | Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. *European Urology Focus*, **2021**, 7, 722-732 | 5.1 | 3 |
| 25 | Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. *American Journal of Clinical Pathology*, **2021**, 155, 588-596 | 1.9 | 3 |

| | | | |
|---|---|---|---|
| 24 | Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis. *Cancers*, **2020**, 12, | 6.6 | 2 |
| 23 | Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy. *Journal of Urology*, **2018**, 200, 559-563 | 2.5 | 2 |
| 22 | Clinical, radiographic, and pathologic description of IgG4-related perivasal fibrosis: a previously undescribed etiology of chronic orchialgia. *Urology*, **2014**, 84, 748-50 | 1.6 | 2 |
| 21 | Uncommon Cancers of the Prostate **2012**, 47-75 | | 2 |
| 20 | Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. *Npj Precision Oncology*, **2021**, 5, 35 | 9.8 | 2 |
| 19 | Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. *Translational Oncology*, **2021**, 14, 100944 | 4.9 | 2 |
| 18 | Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?. *Clinical Genitourinary Cancer*, **2019**, 17, e209-e215 | 3.3 | 1 |
| 17 | Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2015**, 33, 4513-4513 | 2.2 | 1 |
| 16 | Upper tract urothelial carcinoma is non-basal and T-cell depleted.. *Journal of Clinical Oncology*, **2018**, 36, 4525-4525 | 2.2 | 1 |
| 15 | Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. *Journal of Clinical Oncology*, **2015**, 33, 158-158 | 2.2 | 1 |
| 14 | Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder.. *Journal of Clinical Oncology*, **2014**, 32, 290-290 | 2.2 | 1 |
| 13 | Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience. *Cancer Cytopathology*, **2021**, 129, 874-883 | 3.9 | 1 |
| 12 | Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 295.e1-295.e8 | 2.8 | 1 |
| 11 | Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. *Journal of Pathology*, **2022**, | 9.4 | 1 |
| 10 | Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience. *Cancer Treatment and Research Communications*, **2020**, 25, 100209 | 2 | 0 |
| 9 | Tumor size and genomic risk in localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 434.e17-434.e22 | 2.8 | 0 |
| 8 | A multidisciplinary approach to optimize primary prostate cancer biobanking.. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 271.e1-271.e7 | 2.8 | 0 |
| 7 | Uncommon Cancers of the Prostate **2017**, 68-96 | | |

| | | |
|---|---|---|
| 6 | Reply by Authors. *Journal of Urology*, **2020**, 203, 536 | 2.5 |
| 5 | Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2015**, 33, 290-290 | 2.2 |
| 4 | Analyses of the transcriptome and metabolome to elucidate the role of HIF1 in clear cell renal cell carcinoma metabolism.. *Journal of Clinical Oncology*, **2015**, 33, 493-493 | 2.2 |
| 3 | Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 379-379 | 2.2 |
| 2 | Perihepatic cystic mass: Zebra or horse?. *CytoJournal*, **2017**, 14, 21 | 1.1 |
| 1 | Pilot study on the correlation of multiphoton microscopy of human testicular tumors with histology.. *Journal of Clinical Oncology*, **2012**, 30, 338-338 | 2.2 |